ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Repros Therapeutics Inc. 

2408 Timberloch Place
Suite B-7
The Woodlands  Texas  77380  U.S.A.
Phone: 281-719-3400 Fax: 281-719-3446


SEARCH JOBS








 Company News
Repros Therapeutics Inc. (RPRX) Shares Tank On Drug Application Setback 10/17/2014 7:15:39 AM
Repros Therapeutics Inc. (RPRX) Release: Androxal® Second Pivotal Study Achieves Superiority In Top Line Analysis For Both Co-Primary Endpoints Versus Marketed Topical Gel In The Treatment Of Secondary Hypogonadism 9/26/2014 7:16:45 AM
FDA Schedules Type B Pre-NDA Meeting With Repros Therapeutics Inc. (RPRX) 9/25/2014 2:24:54 PM
Repros Therapeutics Inc. (RPRX) Gives Update On Androxal® With Respect To Recent FDA Advisory Panel Outcome And Announces Upcoming Presentation At Biocentury 9/22/2014 8:11:03 AM
Repros Therapeutics Inc. (RPRX)'s Testosterone Drug Found Superior To AbbVie (ABBV)'s Androgel In Study 8/28/2014 6:09:13 AM
Repros Therapeutics Inc. (RPRX) Reports Second Quarter 2014 Financial Results 8/11/2014 7:51:03 AM
Repros Therapeutics Inc. (RPRX) Release: FDA Confirms Sperm And Testosterone Endpoints As Key Parameters For Assessment Of Androxal® Versus Approved Topical Gel And Placebo 7/16/2014 7:40:19 AM
Repros Therapeutics Inc. (RPRX) Fully Enrolls Second Previously Announced Head To Head Study Of Androxal® Versus The Leading Topical Testosterone Gel 5/13/2014 11:39:36 AM
Repros Therapeutics Inc. (RPRX) Reports First Quarter 2014 Financial Results 5/12/2014 9:04:45 AM
Repros Therapeutics Inc. (RPRX) Release: FDA Recommends Sperm Endpoints As Key Parameters For Assessment Of Androxal® Versus Approved Topical Gel 4/30/2014 5:15:02 PM
12345678910...